Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Praxis Precision Medicines, Inc.

A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ:PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.